Nothing Special   »   [go: up one dir, main page]

PL3495358T3 - Podstawione amidem związki heterocykliczne przydatne jako modulatory odpowiedzi il-12, il-23 i/lub ifn-alfa - Google Patents

Podstawione amidem związki heterocykliczne przydatne jako modulatory odpowiedzi il-12, il-23 i/lub ifn-alfa

Info

Publication number
PL3495358T3
PL3495358T3 PL18197550T PL18197550T PL3495358T3 PL 3495358 T3 PL3495358 T3 PL 3495358T3 PL 18197550 T PL18197550 T PL 18197550T PL 18197550 T PL18197550 T PL 18197550T PL 3495358 T3 PL3495358 T3 PL 3495358T3
Authority
PL
Poland
Prior art keywords
modulators
amide
substituted heterocyclic
heterocyclic compounds
compounds useful
Prior art date
Application number
PL18197550T
Other languages
English (en)
Inventor
Ryan M. MOSLIN
David S. Weinstein
Stephen T. Wrobleski
John S. Tokarski
Amit Kumar
Douglas G. Batt
Shuqun Lin
Chunijan LIU
Steven H. Spergel
Yanlei Zhang
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49876960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3495358(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL3495358T3 publication Critical patent/PL3495358T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL18197550T 2012-11-08 2013-11-07 Podstawione amidem związki heterocykliczne przydatne jako modulatory odpowiedzi il-12, il-23 i/lub ifn-alfa PL3495358T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261723840P 2012-11-08 2012-11-08
PCT/US2013/068846 WO2014074661A1 (en) 2012-11-08 2013-11-07 AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES
EP13811640.5A EP2922846B1 (en) 2012-11-08 2013-11-07 Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha
EP18197550.9A EP3495358B8 (en) 2012-11-08 2013-11-07 Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses

Publications (1)

Publication Number Publication Date
PL3495358T3 true PL3495358T3 (pl) 2022-06-27

Family

ID=49876960

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18197550T PL3495358T3 (pl) 2012-11-08 2013-11-07 Podstawione amidem związki heterocykliczne przydatne jako modulatory odpowiedzi il-12, il-23 i/lub ifn-alfa
PL13811640T PL2922846T3 (pl) 2012-11-08 2013-11-07 Podstawione amidem związki heterocykliczne przydatne jako modulatory il-12, il-23 i/lub ifn-alfa

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL13811640T PL2922846T3 (pl) 2012-11-08 2013-11-07 Podstawione amidem związki heterocykliczne przydatne jako modulatory il-12, il-23 i/lub ifn-alfa

Country Status (39)

Country Link
US (6) USRE47929E1 (pl)
EP (3) EP2922846B1 (pl)
JP (3) JP6407159B2 (pl)
KR (1) KR102195194B1 (pl)
CN (1) CN104884454B (pl)
AR (1) AR094452A1 (pl)
AU (4) AU2013341186B2 (pl)
BR (1) BR112015010102B1 (pl)
CA (1) CA2890981C (pl)
CL (1) CL2015001231A1 (pl)
CY (2) CY1121188T1 (pl)
DK (2) DK3495358T3 (pl)
EA (1) EA028814B1 (pl)
ES (2) ES2702148T3 (pl)
FI (1) FIC20230028I1 (pl)
FR (1) FR23C1030I2 (pl)
HK (1) HK1215255A1 (pl)
HR (2) HRP20220766T1 (pl)
HU (3) HUE041750T2 (pl)
IL (1) IL238610A0 (pl)
LT (3) LT2922846T (pl)
MA (1) MA38072A1 (pl)
MX (2) MX2015005731A (pl)
MY (2) MY175448A (pl)
NL (1) NL301238I2 (pl)
NO (1) NO2023032I1 (pl)
NZ (1) NZ708859A (pl)
PE (1) PE20150944A1 (pl)
PH (1) PH12015501004B1 (pl)
PL (2) PL3495358T3 (pl)
PT (2) PT2922846T (pl)
RS (2) RS58187B1 (pl)
SG (3) SG10201706897TA (pl)
SI (2) SI2922846T1 (pl)
TR (1) TR201820824T4 (pl)
TW (1) TWI605041B (pl)
UY (1) UY35126A (pl)
WO (1) WO2014074661A1 (pl)
ZA (1) ZA201504052B (pl)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3495358T3 (pl) * 2012-11-08 2022-06-27 Bristol-Myers Squibb Company Podstawione amidem związki heterocykliczne przydatne jako modulatory odpowiedzi il-12, il-23 i/lub ifn-alfa
MX2015005561A (es) 2012-11-08 2015-07-23 Squibb Bristol Myers Co Compuestos de pirimidina sustituidos con alquil-amida utiles en la modulacion de interleucina 12 (il-12) interleucina 23 (il-23) y/o interferon alfa (ifn alfa).
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
US10273237B2 (en) 2013-12-10 2019-04-30 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses
WO2015123453A1 (en) * 2014-02-14 2015-08-20 Portola Pharmaceuticals, Inc. Pyridazine compounds as jak inhibitors
CN112851578A (zh) 2015-11-26 2021-05-28 诺华股份有限公司 二氨基吡啶衍生物
ES2930198T3 (es) 2016-10-14 2022-12-07 Nimbus Lakshmi Inc Inhibidores de TYK2 y usos de los mismos
CA3040286A1 (en) 2016-10-21 2018-04-26 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
AR110351A1 (es) * 2016-12-13 2019-03-20 Bristol Myers Squibb Co COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
CA3055209A1 (en) 2017-03-08 2018-09-13 Nimbus Lakshmi, Inc. Tyk2 inhibitors, uses, and methods for production thereof
ES2864450T3 (es) * 2017-03-30 2021-10-13 Bristol Myers Squibb Co Proceso para la preparación de 6-(ciclopropanamido)-4-((2-metoxi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-N-(metil-d3)piridazina-3-carboxamida
EA202091269A1 (ru) * 2017-11-21 2020-08-07 Бристол-Маерс Сквибб Компани Сульфон-, пиридин-, алкил-, амид-замещенные гетероарильные соединения
US10508113B2 (en) 2018-03-12 2019-12-17 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
ES2944733T3 (es) * 2018-03-22 2023-06-23 Bristol Myers Squibb Co Compuestos heterocíclicos que comprenden piridina, útiles como moduladores de las respuestas a IL-12, IL-23 y/o IFN alfa
CN112236425A (zh) * 2018-05-31 2021-01-15 百时美施贵宝公司 6-(环丙烷甲酰氨基)-4-((2-甲氧基-3-(1-甲基-1h-1,2,4-三唑-3-基)苯基)氨基)-n-(甲基-d3)哒嗪-3-甲酰胺的结晶形式
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
CN113271940A (zh) 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
MX2021004538A (es) * 2018-10-22 2021-09-10 Esker Therapeutics Inc Inhibidores de tyk2 y sus usos.
IL282840B1 (en) * 2018-10-30 2024-11-01 Bristol Myers Squibb Company Substituted amide heterocyclic compounds for the treatment of conditions involving the regulation of IL-12, IL-23 AND/OR IFN-ALPHA
US11053241B2 (en) 2018-11-30 2021-07-06 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
CA3126034A1 (en) 2019-01-23 2020-07-30 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2020156311A1 (zh) * 2019-01-28 2020-08-06 江苏豪森药业集团有限公司 一种哒嗪类衍生物抑制剂、其制备方法和应用
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
KR20210121140A (ko) * 2019-01-30 2021-10-07 브리스톨-마이어스 스큅 컴퍼니 아미드-이치환된 피리딘 또는 피리다진 화합물
CN114269336A (zh) * 2019-04-30 2022-04-01 细胞基因公司 包含阿普斯特和tyk2抑制剂的联合疗法
US11357775B2 (en) 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
CN114174284A (zh) * 2019-06-12 2022-03-11 百时美施贵宝公司 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的结晶盐形式
US20230167082A1 (en) * 2019-07-16 2023-06-01 Bristol-Myers Squibb Company Prodrugs in the modulation of interleukin
JP2022542704A (ja) 2019-08-01 2022-10-06 インテグラル バイオサイエンシーズ プライベート リミテッド キナーゼインヒビターとしての複素環式化合物およびその使用
WO2021050964A1 (en) 2019-09-13 2021-03-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CA3151137A1 (en) 2019-09-18 2021-03-25 Sherif Ibrahim Farag Badawy Dosage forms for tyk2 inhibitors
WO2021129467A1 (zh) * 2019-12-27 2021-07-01 苏州科睿思制药有限公司 一种bms-986165晶型及其制备方法和用途
WO2021143498A1 (zh) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 一种Deucravacitinib的晶型及其制备方法和用途
WO2021143430A1 (zh) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型及其制备方法和用途
WO2021170046A1 (en) * 2020-02-26 2021-09-02 Beigene, Ltd. Tyk-2 inhibitor
PL4038063T3 (pl) * 2020-03-11 2024-07-15 Beijing Innocare Pharma Tech Co., Ltd. Związki heterocykliczne do hamowania aktywności tyk2
WO2021204626A1 (en) * 2020-04-06 2021-10-14 Almirall, S.A. Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
CN113563309A (zh) * 2020-04-28 2021-10-29 浙江海正药业股份有限公司 吡啶类衍生物及其制备方法和用途
CN115715287A (zh) * 2020-04-28 2023-02-24 百时美施贵宝公司 作为IL-12、IL-23和/或IFNα调节剂的经取代的N-(甲基-d3)哒嗪-3-甲酰胺或N-(甲基-d3)-烟酰胺化合物
CN113735837B (zh) * 2020-05-28 2023-09-01 江苏先声药业有限公司 哒嗪类化合物及其用途
CN113735836B (zh) * 2020-05-28 2023-05-30 江苏先声药业有限公司 哒嗪类化合物及其应用
CN113773262B (zh) * 2020-06-09 2024-08-09 江苏先声药业有限公司 哒嗪类化合物
KR20230043887A (ko) * 2020-07-24 2023-03-31 상하이 한서 바이오메디컬 컴퍼니 리미티드 피리다진 유도체 유리 염기의 결정 형태, 및 이의 제조 방법 및 이의 용도
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
CN114057651A (zh) * 2020-07-31 2022-02-18 正大天晴药业集团股份有限公司 含酰胺基的tyk2抑制剂化合物
WO2022021684A1 (zh) * 2020-07-31 2022-02-03 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型csv及其制备方法和用途
MX2023003194A (es) 2020-09-18 2023-04-13 Bristol Myers Squibb Co Formas de dosificacion para inhibidores de tirosina cinasa 2 (tyk2) que comprenden nucleos hinchables.
CN116615200A (zh) * 2020-10-20 2023-08-18 杭州领业医药科技有限公司 哒嗪衍生物的晶型
CN116490501A (zh) * 2020-11-12 2023-07-25 上海睿跃生物科技有限公司 酪氨酸激酶2(tyk2)降解化合物和使用方法
WO2022105771A1 (zh) * 2020-11-17 2022-05-27 江苏恒瑞医药股份有限公司 含氮杂环类衍生物、其制备方法及其在医药上的应用
CN116547276A (zh) * 2020-12-08 2023-08-04 正大天晴药业集团股份有限公司 含酰胺基和杂环烷基的tyk2抑制剂化合物
AU2022214313A1 (en) 2021-01-29 2023-08-17 Bristol-Myers Squibb Company Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
CA3206501A1 (en) 2021-02-02 2022-08-11 Shaun Abbott Gpr84 antagonists and uses thereof
WO2022167445A1 (en) 2021-02-02 2022-08-11 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
CN114907326A (zh) * 2021-02-06 2022-08-16 正大天晴药业集团股份有限公司 含酰胺基和联环的tyk2抑制剂化合物
TW202233600A (zh) * 2021-02-06 2022-09-01 大陸商正大天晴藥業集團股份有限公司 含聯環的ｔｙｋ２抑制劑化合物、藥物組合物及其用途
TW202246233A (zh) 2021-02-19 2022-12-01 英商蘇多生物科學有限公司 Tyk2抑制劑及其用途
WO2022175752A1 (en) 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
EP4301756A1 (en) 2021-03-05 2024-01-10 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
JP2024510274A (ja) * 2021-03-16 2024-03-06 アンルイ バイオメディカル テクノロジー （グァンヂョウ） カンパニー リミテッド アミノヘテロアリール化合物および組成物
WO2022212181A1 (en) 2021-03-29 2022-10-06 Bristol-Myers Squibb Company Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CN117177960A (zh) * 2021-03-30 2023-12-05 浙江文达医药科技有限公司 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途
CN115197196B (zh) * 2021-04-06 2024-06-18 扬子江药业集团有限公司 Tyk2抑制剂及其用途
AU2022268464A1 (en) 2021-05-04 2023-12-21 Shanghai Zheye Biotechnology Co. Ltd. Nitrogen-containing heterocyclic pyridine compound
US20240270723A1 (en) 2021-05-14 2024-08-15 Bristol-Myers Squibb Company Substituted heterocyclic compounds
KR20240008337A (ko) 2021-05-14 2024-01-18 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
WO2022241172A1 (en) 2021-05-14 2022-11-17 Bristol-Myers Squibb Company Substituted heterocyclic compounds
US11866414B2 (en) * 2021-05-14 2024-01-09 Bristol-Myers Squibb Company Substituted heterocyclic compounds
WO2022253335A1 (zh) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 含磺酰基的芳基类化合物及其应用
CN117500796A (zh) * 2021-06-22 2024-02-02 南京明德新药研发有限公司 亚磺酰亚胺类化合物及其应用
CN117794911A (zh) * 2021-07-15 2024-03-29 南京明德新药研发有限公司 含硫/磷的芳基类化合物及其应用
EP4387968A1 (en) 2021-08-20 2024-06-26 Bristol-Myers Squibb Company Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
US20240368122A1 (en) * 2021-08-21 2024-11-07 Relay Therapeutics, Inc. Jak2 inhibitors and methods of use thereof
IL311624A (en) 2021-09-23 2024-05-01 Bristol Myers Squibb Co Methods for treating hair loss disorders with TYK2 inhibitors
EP4408527A2 (en) 2021-09-30 2024-08-07 Bristol-Myers Squibb Company Methods for determining responsiveness to tyk2 inhibitors
AU2022378463A1 (en) 2021-10-25 2024-05-09 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
WO2023076515A1 (en) 2021-10-28 2023-05-04 Bristol-Myers Squibb Company Topical formulations of deucravacitinib
EP4441043A1 (en) 2021-12-01 2024-10-09 Teva Czech Industries s.r.o Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates
TW202339749A (zh) * 2021-12-16 2023-10-16 大陸商凌科藥業有限公司 Ｔｙｋ２抑制劑及其組合物和方法
WO2023108536A1 (en) * 2021-12-16 2023-06-22 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
EP4206196A1 (en) 2021-12-29 2023-07-05 Almirall S.A. Pyrimidine substituted derivatives as tyk2 inhibitors
CN116693449A (zh) 2022-03-04 2023-09-05 上海致根医药科技有限公司 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
WO2023231997A1 (zh) * 2022-05-31 2023-12-07 上海华汇拓医药科技有限公司 一种哒嗪类化合物、其制备方法和用途
WO2024020221A1 (en) 2022-07-21 2024-01-25 Arvinas Operations, Inc. Modulators of tyk2 proteolysis and associated methods of use
TW202415650A (zh) 2022-08-02 2024-04-16 英商利米那生物科技有限公司 芳基-三唑基及相關gpr84拮抗劑及其用途
TW202416950A (zh) 2022-08-02 2024-05-01 英商利米那生物科技有限公司 雜芳基甲醯胺及相關gpr84拮抗劑及其用途
TW202416972A (zh) 2022-08-02 2024-05-01 英商利米那生物科技有限公司 經取代之吡啶酮gpr84拮抗劑及其用途
WO2024102683A1 (en) 2022-11-08 2024-05-16 Bristol-Myers Squibb Company Substituted heterocyclic compounds
TW202430168A (zh) 2022-12-16 2024-08-01 印度商阿蘭比克製藥有限公司 Tyk2假激酶配體及其用途
CN116284040B (zh) * 2023-01-05 2024-05-28 华润医药研究院（深圳）有限公司 含氮杂环类化合物及其医药用途
WO2024165000A1 (zh) * 2023-02-07 2024-08-15 上海华汇拓医药科技有限公司 一种哒嗪类化合物、其制备方法和用途
CN116162093B (zh) * 2023-04-25 2023-06-23 中南大学湘雅医院 一种tyk2抑制剂化合物及其用途
CN118593504A (zh) * 2024-06-03 2024-09-06 北京大学第三医院（北京大学第三临床医学院） 氘可来昔替尼或其盐在制备pvns药物方面的新用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075113A1 (fr) 1999-06-09 2000-12-14 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives carboxamide heterocycliques
JP4622047B2 (ja) * 1999-06-09 2011-02-02 アステラス製薬株式会社 新規なヘテロ環カルボキサミド誘導体
AU5108000A (en) * 1999-06-10 2001-01-02 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
CA2356544C (en) 2000-10-03 2006-04-04 Warner-Lambert Company Pyridotriazines and pyridopyridazines
EA011686B1 (ru) 2002-07-15 2009-04-28 Уайт Способ модуляции развития и функций т-клеток-хелперов
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
EP2547338A2 (en) * 2010-03-17 2013-01-23 F. Hoffmann-La Roche AG Imidazopyridine compounds, compositions and methods of use
JP5822934B2 (ja) 2010-09-15 2015-11-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アザベンゾチアゾール化合物、組成物及び使用方法
JP2013542966A (ja) 2010-11-19 2013-11-28 エフ．ホフマン−ラ ロシュ アーゲー ピラゾロピリジンならびにｔｙｋ２阻害剤としてのピラゾロピリジン及びそれらの使用
EP2762476A4 (en) 2011-09-30 2015-03-25 Taiho Pharmaceutical Co Ltd 1,2,4-triazine-6-carboxamide derivative
MX352928B (es) * 2012-01-10 2017-12-13 Hoffmann La Roche Compuestos de piridazina-amida.
UY34807A (es) * 2012-05-16 2013-12-31 Novartis Ag Derivados monocíclicos de heteroarilcicloalquil- diamina
US9040530B2 (en) * 2012-06-22 2015-05-26 Portola Pharmaceuticals, Inc. 1,2,4-triazine-6-carboxamide kinase inhibitors
US10112928B2 (en) * 2012-10-19 2018-10-30 Hoffmann-La Roche Inc. Inhibitors of SYK
MX2015005561A (es) 2012-11-08 2015-07-23 Squibb Bristol Myers Co Compuestos de pirimidina sustituidos con alquil-amida utiles en la modulacion de interleucina 12 (il-12) interleucina 23 (il-23) y/o interferon alfa (ifn alfa).
EA028526B1 (ru) 2012-11-08 2017-11-30 Бристол-Майерс Сквибб Компани АЛКИЛАМИДЗАМЕЩЕННЫЕ ПИРИДИЛЬНЫЕ СОЕДИНЕНИЯ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОТВЕТОВ, ОПОСРЕДУЕМЫХ IL-12, IL-23 И/ИЛИ IFNα
PL3495358T3 (pl) 2012-11-08 2022-06-27 Bristol-Myers Squibb Company Podstawione amidem związki heterocykliczne przydatne jako modulatory odpowiedzi il-12, il-23 i/lub ifn-alfa
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
ES2864450T3 (es) * 2017-03-30 2021-10-13 Bristol Myers Squibb Co Proceso para la preparación de 6-(ciclopropanamido)-4-((2-metoxi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-N-(metil-d3)piridazina-3-carboxamida

Also Published As

Publication number Publication date
HUE059409T2 (hu) 2022-11-28
MY194668A (en) 2022-12-12
EP2922846B1 (en) 2018-10-03
UY35126A (es) 2014-05-30
PH12015501004A1 (en) 2015-07-27
HUE041750T2 (hu) 2019-05-28
USRE47929E1 (en) 2020-04-07
PL2922846T3 (pl) 2019-03-29
BR112015010102B1 (pt) 2022-02-08
NZ708859A (en) 2018-11-30
CN104884454B (zh) 2017-11-28
EA028814B1 (ru) 2018-01-31
SG11201503399XA (en) 2015-05-28
KR102195194B1 (ko) 2020-12-24
US9505748B2 (en) 2016-11-29
CY2023017I1 (el) 2023-11-15
MX2020003156A (es) 2020-07-29
EP3495358B1 (en) 2022-04-27
CY2023017I2 (el) 2024-02-16
EP3495358A1 (en) 2019-06-12
SI3495358T1 (sl) 2022-06-30
JP2020002157A (ja) 2020-01-09
RS58187B1 (sr) 2019-03-29
CY1121188T1 (el) 2020-05-29
US11021475B2 (en) 2021-06-01
MA38072A1 (fr) 2016-07-29
FR23C1030I1 (fr) 2023-10-13
US20170022192A1 (en) 2017-01-26
JP2016506369A (ja) 2016-03-03
HK1215255A1 (zh) 2016-08-19
CA2890981A1 (en) 2014-05-15
ES2914793T3 (es) 2022-06-16
US20150299183A1 (en) 2015-10-22
HUS2300025I1 (hu) 2023-08-28
AR094452A1 (es) 2015-08-05
BR112015010102A2 (pt) 2017-07-11
HRP20181937T1 (hr) 2019-01-25
ZA201504052B (en) 2017-11-29
ES2702148T3 (es) 2019-02-27
RS63328B1 (sr) 2022-07-29
TWI605041B (zh) 2017-11-11
DK3495358T3 (da) 2022-05-23
US10526321B2 (en) 2020-01-07
DK2922846T3 (en) 2019-01-21
CN104884454A (zh) 2015-09-02
FR23C1030I2 (fr) 2024-10-25
US20220356180A1 (en) 2022-11-10
US20180265504A1 (en) 2018-09-20
AU2017201076B2 (en) 2018-11-15
PE20150944A1 (es) 2015-06-20
JP6407159B2 (ja) 2018-10-17
PH12015501004B1 (en) 2015-07-27
SI2922846T1 (sl) 2019-04-30
TW201422593A (zh) 2014-06-16
JP2018154636A (ja) 2018-10-04
EP3495358B8 (en) 2022-06-08
IL238610A0 (en) 2015-06-30
SG10201706897TA (en) 2017-09-28
EA201590917A1 (ru) 2015-09-30
NL301238I2 (nl) 2023-10-04
US20200071315A1 (en) 2020-03-05
WO2014074661A1 (en) 2014-05-15
AU2018267545A1 (en) 2018-12-13
EP4071144A1 (en) 2022-10-12
JP6585231B2 (ja) 2019-10-02
AU2017201076A1 (en) 2017-03-09
TR201820824T4 (tr) 2019-01-21
NO2023032I1 (en) 2023-08-25
FIC20230028I1 (fi) 2023-08-28
LTPA2023523I1 (pl) 2023-09-11
KR20150081339A (ko) 2015-07-13
AU2020203967B2 (en) 2020-10-22
EP2922846A1 (en) 2015-09-30
HRP20220766T1 (hr) 2022-09-16
CL2015001231A1 (es) 2015-08-28
AU2013341186B2 (en) 2017-03-30
CA2890981C (en) 2022-07-05
MX2015005731A (es) 2015-09-16
MY175448A (en) 2020-06-29
AU2013341186A1 (en) 2015-07-02
LT3495358T (lt) 2022-05-25
LT2922846T (lt) 2018-12-10
PT3495358T (pt) 2022-06-02
SG10201706985UA (en) 2017-10-30
US10000480B2 (en) 2018-06-19
AU2020203967A1 (en) 2020-07-16
PT2922846T (pt) 2018-12-19
AU2018267545B2 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
HUS2300025I1 (hu) Amidszubsztituált heterociklikus vegyületek mint IL-12, IL-23 és/vagy IFN-ALFA modulátorai
HRP20191368T1 (hr) Alkil-amid supstituirani piridil spojevi korisni kao modulatori il-12, il-23 i/ili ifnalfa odgovora
EP2922841B8 (en) Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
GB201301626D0 (en) Composition comprising 15-OHEPA and methods of using the same
PL2988756T3 (pl) Formulacja środka kontrastowego i powiązany sposób jego wytwarzania
EP2995308A4 (en) ANTI-HYPOXIC PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP3074028A4 (en) Activity enhancing curcumin compositions and methods of use
EP2807256A4 (en) MYONECTIN (CTRP15), COMPOSITION COMPRISING SAME AND METHODS OF USE
EP2900916A4 (en) STITCHING COLMATANT MATERIAL AND METHOD OF USE
HK1210264A1 (en) Method of evaluating cellulite and method of evaluating cellulite- effective drug using fibulin-3 and/or sarcoglycan gamma as an indicator -3 /
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
EP2900783A4 (en) DEHYDRATED GEL COMPOSITIONS AND USE METHOD THEREFOR
ZA201502205B (en) Ectoparasitic treatment method and composition
GB201207064D0 (en) Pharmaceutical compositions comprising 15-hetre and methods of using the same
AU2013902122A0 (en) Ectoparasitic Treatment Method and Composition
GB201301928D0 (en) Composition and method of use thereof